New JN.1 COVID shot shows promise in High-Risk groups

NCT ID NCT07079670

Completed ⭐️ VACCINE ⭐️ Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new vaccine designed to protect against the Omicron JN.1 variant of COVID-19. About 120 adults aged 65 and older, and teens and adults aged 12 to 64 with health conditions that increase COVID-19 risk, received one dose. Researchers checked how well the vaccine boosted immunity and monitored safety for 6 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19 SARS-COV-2 INFECTION

Contacts and locations

Locations

Investigational Site Number US047

Austin, Texas, 78705-3298, United States
Investigational Site Number US073

Tomball, Texas, 77375, United States
Investigational Site Number US294

Lafayette, Louisiana, 70508, United States
Investigational Site Number US326

Omaha, Nebraska, 68134, United States
Investigational Site Number US381

Cincinnati, Ohio, 45246-2316, United States
Investigational Site Number US391

Pleasant View, Utah, 84404-4791, United States
Investigational Site Number US395

Melrose Park, Illinois, 60160, United States
Investigational Site Number US404

Phoenix, Arizona, 85044, United States
Investigational Site Number US406

Lenexa, Kansas, 66219, United States
Investigational Site Number US407

Southfield, Michigan, 48076-5412, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.